Connected Drug Injection Devices Market, 2024 - Featuring a Deep Dive Analysis of Enable Wearable Injectors, Insulin Pens & Third Party Devices

DUBLIN, Nov. 23, 2018 /PRNewswire/ --

The "Connected Drug Injection Devices to 2024" report has been added to ResearchAndMarkets.com's offering.

For self-administration, adherence with drug therapy and disease management protocols has become a primary concern within the healthcare and pharmaceutical industries. For chronic conditions adherence has a direct effect on the patient's quality-of-life. Connected drug injection devices - drug injection devices that are designed to address the patient adherence issue by reminding and recording data about patient dosing activity and making it available to HCPs - are gaining interest among industry and managed care participants.

Efforts to enhance adherence have a non-negligible effect on drug formulations and delivery decisions and are a significant factor in the prescribing decisions of most physicians. The connected device ecosystem includes OEM device suppliers, drug developers, human factors consultants and aftermarket third-party devices.

Connected Drug Injection Devices - What You Will Learn

• What drug injection devices incorporate wireless connectivity technology, how do they work and what new capabilities do they offer to patients and their HCPs?
• What benefits do connected drug injectors provide to patients in the area of improved adherence? Patient reported outcomes? HCP/patient communication?
• What therapeutic areas are the current focus of connected devices?
• Who are the companies behind the push to connected injection devices? What are their development activities and corporate alliances and affiliations
• What is the importance of pharma-device alliances and design partnerships on connected drug injection device commercialization and market access?
• What does the current market for connected drug injection devices look like? What will it look like in 2024?
• What are the key market drivers for the growth of connected injection devices?

Key Topics Covered:

1. Executive Summary

2. Injectable Drug Development Trends

• The Rapid Rise of Prefilled Injection Devices
• Factors Driving Drug Self-Administration
• Connectivity Technologies
• Competitive Landscape

3. Connected Devices Deep Dive Analysis

• Enable Wearable Injector (Enable Injections)
• OmniPod (Insulet)
• RebiSmart (Merck Serono)
• BETACONNECT (Bayer HealthCare)
• easypod (EMD Serono)
• Axis-D Connect (Haselmeier)
• Flexi-Q eMU (Elcam Medical)
• YpsoMate/SmartPilot (Ypsomed AG)
• Onejet (Biocorp)
• Datapen (Biocorp)
• KiCoPen (Cambridge Consultants)
• Insulin Pens
• InPen (Companion Medical)
• Esysta Pen (Emperra)
• Third Party Devices
• Gocap (Common Sensing)
• EASYLOG (Biocorp)
• Bee (Vigilant)
• Veta EpiPen Smart Case (Aterica)

4. Near-term Markets and Forecasts

• Anaphylaxis
• Autoimmune Disease
• Multiple Sclerosis
• Cardiovascular
• Diabetes
• Hormone Replacement

5. Market Factors

• Regulatory Requirements
• Data Security
• Patient Acceptance

6. Company Profiles

• Aterica
• Bayer HealthCare
• Biocorp
• Cambridge Consultants
• Common Sensing
• Companion Medical
• EMD Serono
• Elcam Medical
• Emperra
• Enable Injections
• Haselmeier
• Insulet
• Merck Serono
• Vigilant
• Ypsomed AG

For more information about this report visit https://www.researchandmarkets.com/research/lzdk7j/connected_drug?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/connected-drug-injection-devices-market-2024---featuring-a-deep-dive-analysis-of-enable-wearable-injectors-insulin-pens--third-party-devices-300754790.html

SOURCE Research and Markets